EUVIMEDSkopri EUVIMED
Multizentrische StudieVergleichsstudieOpen access · CC BY-NC 4.0

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

Yee Hui Yeo iD, Sepideh Mehravar, Ellen Choi, Ju Dong Yang iD, Hyun-Seok Kim, Yun Wang, Aarshi Vipani, Hirsh D Trivedi, Walid Ayoub, Parnian Naji, Alexander Kuo, Chun-Ying Wu iD and 2 more

Alimentary Pharmacology & Therapeutics · 2026-06 · 63 (12) · 1673-1684

DOI: 10.1111/apt.70619 ↗

At a glance

Multizentrische Studie in Alimentary Pharmacology & Therapeutics, published online on 2026-03-17. Written by Yee Hui Yeo and 13 co-authors. Institution: Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA. Major MEDLINE topics: Acamprosate, Baclofen, Alcohol Deterrents, Liver Cirrhosis, Alcoholic. Cited 7 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY-NC 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Acamprosate is generally considered safe in patients with liver disease because it is renally cleared. Baclofen has been shown to be safe and effective in patients with alcohol use disorder and alcohol‐associated cirrhosis. Both medications are guideline‐endorsed pharmacotherapies for patients with alcohol‐associated cirrhosis. However, the safety of baclofen relative to acamprosate remains uncertain.

Aims

To compare the safety profiles of baclofen and acamprosate in patients with alcohol‐associated cirrhosis.

Methods

We conducted a nationwide, multicenter cohort study using a target trial emulation framework. Adults with compensated alcohol‐associated cirrhosis who received a first prescription of baclofen or acamprosate within 6 months of diagnosis were included. Propensity score matching (1:1) was used to balance 60 covariates. The primary outcome was major adverse liver outcomes (MALO), defined as a composite of hepatic decompensation events within 12 months. Secondary outcomes included individual decompensation events and mortality.

Results

After matching, 571 baclofen and 571 acamprosate initiators were analysed. The 1‐year incidence of MALO was higher in the baclofen group (34.3%) than in the acamprosate group (27.4%), corresponding to a hazard ratio (HR) of 1.32 (95% CI, 1.02–1.70). Among individual events, baclofen was associated with a higher risk of hepatic encephalopathy (HR 1.80; 95% CI, 1.21–2.69). No significant differences in other individual events or mortality were observed. Subgroup analyses suggested greater risk among patients aged 56–70 years.

Conclusions

In this large real‐world study, baclofen was associated with a higher risk of hepatic encephalopathy compared with acamprosate in patients with compensated alcohol‐associated cirrhosis.

Subjects

MeSH terms (MEDLINE)

AcamprosateBaclofenAlcohol DeterrentsLiver Cirrhosis, AlcoholicHumansMiddle AgedFemaleMaleAgedCohort StudiesTreatment OutcomeAlcoholism

Author keywords

acamprosatealcohol‐associated cirrhosisbaclofenhepatic decompensationtarget trial emulation

Substances

AcamprosateBaclofenAlcohol Deterrents

Authors and institutions

  • Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Department of Internal Medicine, Englewood Hospital and Medical Center, Englewood, New Jersey, USA.
  • Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Department of Internal Medicine, Dell Medical School, The University of Texas at Austin, Austin, Texas, USA.
  • Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.

ORCID profiles: Yee Hui Yeo, Ju Dong Yang, Chun-Ying Wu, Lorenzo Leggio, Juan Pablo Arab

Cite

APA

Yeo, Y. H., Mehravar, S., Choi, E., Yang, J. D., Kim, H. S., Wang, Y., Vipani, A., Trivedi, H. D., Ayoub, W., Naji, P., Kuo, A., Wu, C. Y., Leggio, L., & Arab, J. P. (2026). Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis. Alimentary Pharmacology & Therapeutics, 63(12), 1673-1684. https://doi.org/10.1111/apt.70619

Vancouver

Yeo YH, Mehravar S, Choi E, Yang JD, Kim HS, Wang Y, et al. Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis. Alimentary Pharmacology & Therapeutics. 2026;63(12):1673-1684. doi:10.1111/apt.70619

BibTeX
@article{Yeo2026,
  author = {Yeo, Yee Hui and Mehravar, Sepideh and Choi, Ellen and Yang, Ju Dong and Kim, Hyun-Seok and Wang, Yun and Vipani, Aarshi and Trivedi, Hirsh D and Ayoub, Walid and Naji, Parnian and Kuo, Alexander and Wu, Chun-Ying and Leggio, Lorenzo and Arab, Juan Pablo},
  title = {Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {63},
  number = {12},
  pages = {1673--1684},
  doi = {10.1111/apt.70619}
}
Start for free →